Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus.

Authors: Broomall EM,Reynolds SM,Jacobson RM,
Address: Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN 55905-0001, USA.
Journal: Postgrad Med.

Publication: 2010 Mar;122(2):121-9. doi: 10.3810/pgm.2010.03.2129.

abstract

In October 2009, the Advisory Committee on Immunization Practices (ACIP) approved a newly licensed vaccine, Cervarix, directed against human papillomavirus (HPV) to prevent cervical cancer. The ACIP also expanded its recommendations against HPV by giving permission to physicians to vaccinate males aged 9 to 26 years with the previously licensed vaccine, Gardasil, to prevent genital warts, in addition to its previous recommendation for females aged 9 to 26 years to prevent cervical cancer and genital warts. The marketing, expense, safety, and reactivity of Gardasil continue to be the subject of controversy. Of the >100 types of HPVs, approximately 40 are sexually transmitted, and HPV is the most common sexually transmitted disease. By age 50 years, 80% of women will have contracted a sexually transmitted HPV infection. While most individuals are clear of infection by 2 years, some types of HPV carry a high risk for progressing to cancer, and HPV is identified in >99% of patients with cervical cancer. Each year in the United States approximately 12,000 women develop cervical cancer and nearly 4000 die of it. Human papillomavirus is also associated with genital warts and other anogenital cancers. The United States has now licensed 2 vaccines against HPV, Gardasil and Cervarix. Gardasil has been shown to be safe and effective in preventing HPV infections by types 6, 11, 16, and 18; types 16 and 18 are associated with 2 high-risk types of cervical cancer and are associated with 70% of all cervical cancers. Types 6 and 11 are associated with 90% of anogenital warts. Cervarix has also been shown to be safe and effective in preventing HPV infections by types 16 and 18, but offers no known protection against anogenital warts.

Related Articles
Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR Recomm Rep. 2007
Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER, Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007 Mar 23; 56(RR-2):1-24.
Review Human papillomavirus and genital cancer.
Indian J Dermatol Venereol Leprol. 2009
Review Human papillomavirus and genital cancer.
Rapose A. Indian J Dermatol Venereol Leprol. 2009 May-Jun; 75(3):236-43; quiz 243-4.
Review Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.
Drugs. 2010
Review Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.
McCormack PL, Joura EA. Drugs. 2010 Dec 24; 70(18):2449-74.
Review Human papillomavirus, cervical cancer, and the vaccines.
Postgrad Med. 2008
Review Human papillomavirus, cervical cancer, and the vaccines.
Tovar JM, Bazaldua OV, Vargas L, Reile E. Postgrad Med. 2008 Jul; 120(2):79-84.
FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP).
MMWR Morb Mortal Wkly Rep. 2010
FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP).
Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2010 May 28; 59(20):630-2.
Preventive and Therapeutic Vaccines against Human Papillomaviruses Associated Cervical Cancers.
Iran J Basic Med Sci. 2012
Preventive and Therapeutic Vaccines against Human Papillomaviruses Associated Cervical Cancers.
Nayereh KG, Khadem G. Iran J Basic Med Sci. 2012 Jan; 15(1):585-601.
Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever.
Virol J. 2010
Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever.
Branco LM, Grove JN, Geske FJ, Boisen ML, Muncy IJ, Magliato SA, Henderson LA, Schoepp RJ, Cashman KA, Hensley LE, et al. Virol J. 2010 Oct 20; 7:279. Epub 2010 Oct 20.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.